F-017
(±)-Flecainide solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H20F6N2O3
化学文摘社编号:
分子量:
414.34
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
certified reference material
质量水平
表单
liquid
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
clinical testing
包装形式
single component solution
储存温度
−20°C
SMILES字符串
O=C(NCC1CCCCN1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F
InChI
1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)
InChI key
DJBNUMBKLMJRSA-UHFFFAOYSA-N
基因信息
human ... SCN5A(6331)
一般描述
Flecainide, marketed under trade names such as Almarytm, Apocard, Ecrinal®, and Flécaine, is a class Ic antiarrhythmic drug used to prevent and treat a variety of cardiac arrhythmias. This Certified Spiking Solution® is suitable for use as a starting material in the preparation of calibrators, controls, or linearity standards in flecainide therapeutic drug monitoring methods by LC/MS or LC that ensure patients remain within the drug′s narrow therapeutic range.
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Ecrinal is a registered trademark of Laboratoires Asepta Corporation Monaco
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes,Central nervous system
储存分类代码
3 - Flammable liquids
WGK
WGK 2
闪点(°F)
49.5 °F - closed cup
闪点(°C)
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Catecholaminergic polymorphic ventricular tachycardia.
Antoine Leenhardt et al.
Circulation. Arrhythmia and electrophysiology, 5(5), 1044-1052 (2012-10-02)
Antiarrhythmic drug treatment after cardioversion of atrial fibrillation.
Ajay Vallakati et al.
Lancet (London, England), 380(9852), 1467-1468 (2012-10-30)
[CME ECG 40. Vertigo with ST elevation in V2. Brugada syndrome].
Ardan M Saguner et al.
Praxis, 102(5), 305-307 (2013-03-01)
Kosuke Doki et al.
Pharmacogenetics and genomics, 22(11), 777-783 (2012-09-04)
To investigate the association between age-related decline in flecainide clearance and CYP2D6 genotype, we conducted a population pharmacokinetic analysis of flecainide using routine therapeutic drug monitoring data. Population pharmacokinetic analysis was performed on retrospective data from 163 genotyped patients treated
Lovely Chhabra et al.
Indian heart journal, 64(4), 404-407 (2012-08-30)
Flecainide (a class 1c antiarrhythmic) produces a dose-dependent decrease in intracardiac conduction. Its well known common electrocardiographic effects are prolongation of PR and QT intervals and the QRS complex duration. We report a case of flecainide toxicity in an elderly
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持